Related Experiment Video

Updated: Jul 19, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation

Melanie Antl1, Marie-Luise von Brühl, Christina Eiglsperger

  • 1Institut für Pharmakologie und Toxikologie der Technischen Universität München, Germany.

Blood
|September 23, 2006
PubMed

Insights

Defective platelet regulation causes arterial thrombosis. This study reveals the IRAG-InsP3RI interaction is crucial for nitric oxide (NO)/cyclic GMP (cGMP) signaling, inhibiting platelet aggregation and preventing thrombosis.

Area of Science:

  • Cardiovascular Biology
  • Platelet Physiology
  • Thrombosis Research

Background:

  • Defective platelet activation/aggregation regulation is a primary cause of arterial thrombosis, a major complication of atherosclerosis.
  • Nitric oxide (NO)/cyclic GMP (cGMP) signaling, mediated by cGMP-dependent protein kinase I (cGKI), is a key inhibitory pathway for platelet activation.
  • The downstream signaling cascade of cGKI in platelet inhibition remains incompletely understood.

Purpose of the Study:

  • To elucidate the downstream regulatory pathway of cGKI involved in platelet inhibition.
  • To investigate the role of the inositol-1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) in NO/cGMP-dependent platelet function.
  • To determine the impact of the IRAG-InsP3RI interaction on arterial thrombosis.

Main Methods:

  • Immunoprecipitation and Western blotting to identify protein complexes in platelets.
  • Site-directed mutagenesis to disrupt IRAG-InsP3RI interaction in IRAGDelta12/Delta12 mutant mice.
  • In vitro platelet aggregation assays and measurement of intracellular calcium transients.
  • Intravital microscopy to assess arterial thrombosis in vivo.

Main Results:

  • IRAG is expressed in platelets and forms a complex with cGKIbeta and InsP3RI.
  • cGKI phosphorylates IRAG at specific serine residues (Ser664 and Ser677).
  • Disruption of the IRAG-InsP3RI interaction abrogates NO/cGMP-dependent inhibition of platelet activation and aggregation, without affecting calcium signaling.
  • IRAGDelta12/Delta12 mutant mice exhibit impaired NO-mediated prevention of arterial thrombosis.

Conclusions:

  • The interaction between IRAG and InsP3RI is essential for the NO/cGMP/cGKI pathway's inhibitory effect on platelet aggregation.
  • This IRAG-InsP3RI complex plays a critical role in regulating platelet function and preventing arterial thrombosis in vivo.
  • Targeting the IRAG-InsP3RI interaction may offer new therapeutic strategies for thrombotic disorders.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...